NCT03541005View on ClinicalTrials.gov

Evaluation of Obex® in Overweight and Obesity

PHASE3CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

September 1, 2019

Study Completion Date

July 3, 2021

Conditions
Overweight and Obesity
Interventions
DIETARY_SUPPLEMENT

Obex

After concluded the six months of treatment, patients will be follow-up during six months without consumption of Obex

DIETARY_SUPPLEMENT

Placebo

After concluded the six months of treatment, patients will be follow-up during six months without consumption of the placebo.

Trial Locations (1)

10400

National Institute of Endocrinology, Havana

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT03541005 - Evaluation of Obex® in Overweight and Obesity | Biotech Hunter | Biotech Hunter